CL2020002637A1 - Métodos de tratamiento de cáncer. - Google Patents

Métodos de tratamiento de cáncer.

Info

Publication number
CL2020002637A1
CL2020002637A1 CL2020002637A CL2020002637A CL2020002637A1 CL 2020002637 A1 CL2020002637 A1 CL 2020002637A1 CL 2020002637 A CL2020002637 A CL 2020002637A CL 2020002637 A CL2020002637 A CL 2020002637A CL 2020002637 A1 CL2020002637 A1 CL 2020002637A1
Authority
CL
Chile
Prior art keywords
compound
formula
cancer treatment
treatment methods
methods
Prior art date
Application number
CL2020002637A
Other languages
English (en)
Inventor
Alison A Armour
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CL2020002637A1 publication Critical patent/CL2020002637A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent

Abstract

La invención descrita en la presente pertenece a los conjugados de suministro de fármaco para terapia dirigida. La invención descrita en la presente se refiere a métodos de tratamiento de cánceres que expresan PSMA con un compuesto de la fórmula 1. La invención descrita en la presente se refiere también a métodos de tratamiento de cánceres que expresan PSMA con un compuesto de la fórmula 1 en pacientes, donde la enfermedad estable resulta después del tratamiento con le compuesto de la fórmula 1.
CL2020002637A 2018-04-17 2020-10-13 Métodos de tratamiento de cáncer. CL2020002637A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862659016P 2018-04-17 2018-04-17
US201862670442P 2018-05-11 2018-05-11

Publications (1)

Publication Number Publication Date
CL2020002637A1 true CL2020002637A1 (es) 2021-04-16

Family

ID=68240292

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002637A CL2020002637A1 (es) 2018-04-17 2020-10-13 Métodos de tratamiento de cáncer.

Country Status (15)

Country Link
US (1) US20210161911A1 (es)
EP (1) EP3781215A4 (es)
JP (2) JP2021522193A (es)
KR (1) KR20210003135A (es)
CN (1) CN112368024A (es)
AU (1) AU2019255692A1 (es)
BR (1) BR112020020961A2 (es)
CA (1) CA3097381A1 (es)
CL (1) CL2020002637A1 (es)
IL (1) IL277981A (es)
MX (1) MX2020010813A (es)
PH (1) PH12020551715A1 (es)
SG (1) SG11202010217YA (es)
TW (1) TW202012000A (es)
WO (1) WO2019204335A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114401947A (zh) 2019-06-21 2022-04-26 省卫生服务机构 靶向前列腺特异性膜抗原的放射性标记化合物
WO2023240135A2 (en) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY194484A (en) * 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
US20170152323A1 (en) * 2015-01-16 2017-06-01 Immunwork Inc. Anti-inflammatory molecules with tissue-targeting functions
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
WO2017117687A1 (en) * 2016-01-10 2017-07-13 British Columbia Cancer Agency Branch 18/19f-labelled compounds which target the prostate specific membrane antigen

Also Published As

Publication number Publication date
MX2020010813A (es) 2021-01-08
CN112368024A (zh) 2021-02-12
JP2024059640A (ja) 2024-05-01
CA3097381A1 (en) 2019-10-24
BR112020020961A2 (pt) 2021-01-19
EP3781215A4 (en) 2021-12-29
JP2021522193A (ja) 2021-08-30
EP3781215A1 (en) 2021-02-24
AU2019255692A1 (en) 2020-11-26
TW202012000A (zh) 2020-04-01
KR20210003135A (ko) 2021-01-11
SG11202010217YA (en) 2020-11-27
PH12020551715A1 (en) 2021-07-26
WO2019204335A1 (en) 2019-10-24
IL277981A (en) 2020-11-30
US20210161911A1 (en) 2021-06-03

Similar Documents

Publication Publication Date Title
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
DOP2019000020A (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CY1125068T1 (el) Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
CL2019002240A1 (es) Dendrímeros terapéuticos.
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
BR112015030377A2 (pt) preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
BR112016027048A8 (pt) uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017018964A2 (pt) uso de plinabulin e métodos para tratar tumor cerebral
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
MX2020001727A (es) Terapia de combinacion.
CL2020002637A1 (es) Métodos de tratamiento de cáncer.
CO2020001107A2 (es) Moduladores terapéuticos del modo inverso de la atp sintasa
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
MX2016001541A (es) Uso de anticuerpo inmunoconjugado anti-muc1 maitansinoide para el tratamiento de tumores solidos.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CY1126079T1 (el) Σκευασματα καψουλας
EA202190457A1 (ru) Конъюгаты для применения в способах лечения рака
EA202092369A1 (ru) Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
BR112019025164A2 (pt) Esquema de dosagem para tesetaxel e capecitabina
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer